AI-powered evaluation using the Model Context Optimization BS Detection Framework, based solely on publicly available website content.
Based on 587 businesses audited.
Medical Devices, Pharma & Biotech BS: GAZYVA (Genentech) (gazyva.com)
GAZYVA.com is a textbook example of high-substance clinical communication constrained by pharmaceutical regulatory templates. The minor BS score is a byproduct of required legal repetitions and the absence of direct clinical data links in the top-level content. It is a highly credible, albeit formulaic, medical resource.
Immediately link the mentions of a study to their respective ClinicalTrials.gov identifiers or PubMed entries to provide a direct proof path. Remove the single review_count placeholder from the metadata as it implies unverified patient testimonials which are inappropriate for high-risk oncology medications. Replace the consumer-grade YOLO (You only live once) language with clinical urgency messaging that better aligns with the serious nature of Lupus Nephritis treatment. Consolidate the repeated safety information into a single global footer or modal to reduce redundant concept repetition across the crawl.
The site exhibits high substance in its body text, specifically detailing pharmaceutical mechanisms like targeting the CD20 antigen on B-cells and providing granular dosing information. However, it earns points for concept repetition due to the federally mandated safety blocks and indications being restated verbatim across multiple pages (e.g., the Hepatitis B Virus and PML warnings). Fluff in headings is minimal, with mostly functional H2 and H3 tags like For US Healthcare Professionals and Indications.
Hydration, modals, and JS dependent content erase entire sections of your page before AI can read them. Audit your AI visible surface to see what survives a script free crawl.
There is zero semantic drift detected across the analyzed pages. The homepage H1/hero promise of GAZYVA Treatment, Indications, Dosing & Safety is directly supported and expanded upon by the safety.html and lupus-nephritis.html sub-pages. Messaging remains consistent, moving from broad therapeutic claims to specific clinical application and safety warnings without contradiction.
Stop the ROI leak caused by technical debt and strategic misalignment. Conduct an Independent Strategic Diagnosis for 1 Euro to identify high impact issues across all audit categories.
The site triggers the maximum penalty for trust theatre as the trust_theatre_flag is true on all pages while showing a review_count of 1 with a proof_links_count of 0. This suggests the presence of a technical review placeholder or unverified endorsement signal common in templated pharmaceutical sites. Additionally, while the site mentions studies (e.g., a study that included previously untreated FL patients), it lacks direct outbound links to ClinicalTrials.gov or DOI citations within the body text.
Proof density is moderate; the site relies heavily on its FDA-approved status as its primary proof point. While specific numbers like ~90-minute infusion are mentioned, the site lacks a direct proof path (outbound links) to the specific peer-reviewed data supporting the Common side effects ratios mentioned in the text. The presence of detailed Boxed Warnings acts as a counter-signal to typical BS, providing negative substance that increases credibility.
To see how the system reconstructs a medical entity graph at scale, review the full Cleveland Clinic Structured Data audit. View the Cleveland Clinic Structured Data Audit for a live example of identity level decomposition and cross page entity mapping.
The site utilizes standard pharmaceutical template fingerprints including Financial Assistance Options, Important Safety Information, and How I receive GAZYVA infusions. It features minor industry clichés such as Seize the opportunity and the consumer-centric YOLO KOLO (You only live once, and so do your kidneys). The value proposition is unique to the specific molecule (obinutuzumab), but the structural layout is a standard Genentech product-site template.
Authority is well-established through correct Organization schema for Genentech and MedicalWebPage schema on deep pages. There are no expert claims without footprint as the site relies on the corporate brand and clinical regulatory approval rather than individual named experts. Technical implementation is clean with established structured data.
The marketing tone is generally sober, though phrases like seize the opportunity lean toward a promotional tone that slightly disconnects from the clinical risk profile described. Most performance claims are directly tied to FDA-approved indications rather than vague breakthroughs. The primary disconnect is the lack of visible evidence (case studies or data visualizations) in the clean text to back up the claim GAZYVA works to break down cancer cells quickly.
Medical Devices, Pharma & Biotech BS: GAZYVA (Genentech) (gazyva.com)
The site perfectly matches the Medical Devices, Pharma & Biotech category. The content is heavily focused on therapeutic areas like follicular lymphoma and lupus nephritis, utilizing industry-standard pharmacological terminology such as CD20 antigen targeting and B-cell elimination.
AI does not interpret your layout visually — it interprets your structure mathematically. Explore the Semantic HTML Technical Framework to understand how heading logic, boundaries, and DOM depth determine what an LLM can retrieve.
“The score of 15 is driven primarily by the Trust and Proof pillar (8 points) due to the technical mismatch of review counts and missing direct citations. Information Density and Commodity Fingerprint contributed 7 points due to necessary regulatory repetition and the use of standardized pharmaceutical web templates. The site is essentially free of semantic drift and authority gaps.”